journal article·2015-03

Enhanced antitumor efficacies of multifunctional nanocomplexes through knocking down the barriers for siRNA delivery

Lu Han, Cui Tang, Chunhua Yin

Biomaterials· Volume 44
Publisher page

Abstract

Multifunctional nanocomplexes (NCs) consisting of urocanic acid-modified galactosylated trimethyl chitosan (UA-GT) conjugates as polymeric vectors, poly(allylamine hydrochloride)-citraconic anhydride (PAH-Cit) as charge-reversible crosslinkers, and vascular endothelial growth factor (VEGF) siRNA as therapeutic genes, were rationally designed to simultaneously overcome the extracellular, cellular, and intracellular barriers for siRNA delivery. The strong physical stability of UA-GT/PAH-Cit/siRNA NCs (UA-GT NCs) at pH 7.4 and 6.5 endowed protection from massive dilution, competitive ions, and ubiquitous nucleases in the blood and tumorous microenvironment. Their internalization into hepato-carcinoma cells was facilitated through the recognition of galactose receptors, followed by effective escape from endosomes/lysosomes owing to the strong buffering capacity of imidazole residues. At the meantime, the endosomal/lysosomal acidity triggered the charge reversal of PAH-Cit in UA-GT NCs, thus evoking their structural disassembly and subsequently accelerated release of siRNA in the cytosol. As a result, robust in vivo performance in terms of both gene silencing and tumor inhibition was achieved by UA-GT NCs at a low siRNA dose. Moreover, neither histological nor hematological toxicity was detected following repeated intravenous administration. Therefore, UA-GT NCs potentially served as an efficient and safe candidate in the treatment of hepatocellular carcinoma through knocking down the overall barriers for siRNA delivery.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (31)

Show source-provided references
1. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy10.1517/17425240802568505 ↗
2. siRNA delivery systems for cancer treatment10.1016/j.addr.2009.04.018 ↗
3. RNAi therapeutics: a potential new class of pharmaceutical drugs10.1038/nchembio839 ↗
4. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice10.1016/j.jconrel.2010.02.023 ↗
5. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery10.1016/j.biomaterials.2010.07.016 ↗
6. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery10.1021/nn204240b ↗
7. Knocking down barriers: advances in siRNA delivery10.1038/nrd2742 ↗
8. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing10.1016/j.jconrel.2009.10.007 ↗
9. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate10.1016/j.biomaterials.2010.03.018 ↗
10. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides10.1016/j.biomaterials.2011.04.053 ↗
11. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery10.1038/nnano.2012.73 ↗
12. Laser-activated gene silencing via gold nanoshell-siRNA conjugates10.1021/nn900469q ↗
13. Biodegradable dextran nanogels for RNA interference: focusing on endosomal escape and intracellular siRNA delivery10.1002/adfm.200801795 ↗
14. Enhanced stability and knockdown efficiency of poly(ethylene glycol)-b-polyphosphoramidate/siRNA micellar nanoparticles by co-condensation with sodium triphosphate10.1007/s11095-011-0408-7 ↗
15. Chitosan-based siRNA delivery systems10.1016/j.jconrel.2013.08.005 ↗
16. Efficient gene delivery by urocanic acid-modified chitosan10.1016/j.jconrel.2003.08.017 ↗
17. Serum tolerance and endosomal escape capacity of histidine-modified pDNA-loaded complexes based on polyamidoamine dendrimer derivatives10.1016/j.biomaterials.2012.07.032 ↗
18. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface charge-reversal polymer assembly and good biocompatibility10.1021/nn3024688 ↗
19. Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release10.1021/nn205023w ↗
20. Polyelectrolyte multilayers fabricated from 'charge-shifting' anionic polymers: a new approach to controlled film disruption and the release of cationic agents from surfaces10.1039/b804953j ↗
21. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery10.1124/pr.58.1.8 ↗
22. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release10.1021/mp400787s ↗
23. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes10.1073/pnas.0703778104 ↗
24. Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines10.1016/S0142-9612(01)00090-4 ↗
25. Development and characterisation of chitosan nanoparticles for siRNA delivery10.1016/j.jconrel.2006.07.021 ↗
26. Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting10.1038/sj.gt.3302997 ↗
27. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice10.1016/j.biomaterials.2012.07.012 ↗
28. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles10.1016/j.ejpb.2012.04.021 ↗
29. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer10.1016/j.jconrel.2008.03.008 ↗
30. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors10.1016/j.biomaterials.2013.08.085 ↗
31. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery10.1016/j.ijpharm.2013.07.069 ↗